We aim to redefine the treatment paradigm of cancer to eliminate it as a cause of death by providing high-quality medicine at low cost. We focus on offering innovative, evidence-based, and affordable therapies across the oncology spectrum. Through continuous research, we ensures improved patient compliance, safety, and an enhanced quality of life.
India’s oncology challenges
India’s vast population is witnessing an alarming rise in cancer incidence.
Factors like ageing, urbanisation, lifestyle changes, pollution, and genetics drive this increase in urban and rural areas.
Our therapeutic focus
We are dedicated to developing groundbreaking biomedical innovations that help extend and enhance the lives of people affected by cancer worldwide.
With over two decades of scientific commitment, Cadila Pharma has built one of the most comprehensive oncology portfolios.
We aim to address unmet clinical needs in a range of cancers, with a combination-focused pipeline that leverages the power of science.
Every molecule, every brand, and every initiative is driven by the goal of making cancer treatment more accessible, affordable, and effective for patients.
We offer innovative immuno-oncology solutions for the treatment of Advanced Non–Small Cell Lung Cancer (NSCLC), designed to enhance the body’s immune response and complement chemotherapy to support improved clinical outcomes and quality of life.
Focused on HER2-positive, haematological, and solid tumour indications, our portfolio offers advanced, affordable biologics that ensure efficacy, safety, and improved patient outcomes.
Our supportive therapies are designed to enhance cancer care by mitigating treatment-related complications and promoting patient recovery. These biologics help maintain treatment continuity, enhance tolerance, and support better overall outcomes for patients undergoing chemotherapy.
Contact Us
Our Story
Businesses
Therapies
Corporate Identification No : U24231GJ1991PLC015132
©2026 Cadila Pharmaceuticals. All rights reserved
